Biological E. Limited

Biological E. Limited (BE) is a privately held Indian biopharmaceutical company established in 1953 by Dr. D.V.K. Raju. Initially incorporated as Biological Products Private Limited, the company began by manufacturing liver extracts and anti-coagulants during India's Swadeshi Movement, a period emphasizing self-reliance in critical healthcare products.

Over the decades, BE has evolved into a globally recognized vaccine manufacturer, supplying over 2 billion doses worldwide. The company's portfolio includes WHO-prequalified vaccines such as the 5-in-1 Pentavalent and Japanese Encephalitis vaccines. BE operates three strategic business units: Branded Formulations, Specialty Generic Injectables, and Vaccines & Biologics.

Headquartered in Hyderabad, Telangana, India, BE employs between 1,000 and 5,000 individuals. The company's corporate identification number (CIN) is U01120TG1953PLC001095. While specific revenue figures are not publicly disclosed, BE's significant presence in the global vaccine market underscores its substantial financial standing.

Biological E. Limited operates state-of-the-art manufacturing facilities in Hyderabad, Telangana, India. These facilities are equipped with advanced technologies to produce a diverse range of pharmaceutical formulations, including vaccines and injectables. The company's manufacturing capabilities are recognized by major regulatory agencies, including the US FDA and the European Medicines Agency (EMA).

Mahima Datla serves as the Chief Executive Officer and Managing Director of Biological E. Limited. Under her leadership, the company has expanded its global footprint and enhanced its product portfolio. Other key executives include Ippagunta Yasodhara Rama Krishna Rao and Rudraju Anand Kumar, who contribute to the strategic direction and operational excellence of the organization.

Biological E. Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals from the US FDA and EMA for its vaccines and biologics, facilitating market access in these regions. Additionally, BE's products are listed in the WHO's prequalification program, enabling supply to UN agencies and other international organizations.

Biological E. Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO prequalification status has been instrumental in facilitating access to these regions, allowing BE to supply essential vaccines and therapeutics to countries in need.

Biological E. Limited's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. The company's WHO prequalification status and regulatory approvals from agencies like the US FDA and EMA have enabled it to mitigate concentration risks and diversify its market presence.

Biological E. Limited has achieved significant milestones with the US Food and Drug Administration (FDA). The company has received approvals for its vaccines and biologics, facilitating market access in the United States. Additionally, BE's manufacturing facilities are registered with the FDA, ensuring compliance with stringent quality standards.

Biological E. Limited's commitment to quality is evidenced by its WHO prequalification status for several vaccines, including the 5-in-1 Pentavalent and Japanese Encephalitis vaccines. This status allows BE to supply vaccines to UN agencies and other international organizations. The company's manufacturing facilities also adhere to European Union Good Manufacturing Practice (EU GMP) standards, ensuring the production of high-quality pharmaceutical products.

In India, Biological E. Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority. The company complies with state drug controller approvals and has obtained export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Biological E. Limited by regulatory agencies such as the US FDA. This absence suggests a strong compliance record and adherence to regulatory standards.

Biological E. Limited operates in a competitive landscape alongside other Indian pharmaceutical companies such as Biocon, Bharat Serums and Vaccines Limited, Wockhardt Ltd., and Syngene International Limited. While specific market share data is not publicly disclosed, BE's extensive product portfolio and global reach position it as a significant player in the vaccine and biologics sector.

Biological E. Limited's key differentiators include its extensive experience in vaccine manufacturing, with over 2 billion doses supplied globally, and its WHO prequalification status for multiple vaccines. The company's commitment to quality is further demonstrated by its adherence to international standards such as EU GMP.

Biological E. Limited's strategic direction focuses on the development and supply of vaccines and biologics, with a commitment to improving global health. The company's future outlook includes expanding its product portfolio and enhancing its manufacturing capabilities to meet the growing demand for vaccines and therapeutics worldwide.

Biological E. Limited has a strong track record in the pharmaceutical industry, with a history of supplying over 2 billion doses of vaccines globally. The company's adherence to international quality standards, including WHO prequalification and EU GMP, underscores its reliability as a supplier. Additionally, BE's regulatory approvals from agencies such as the US FDA and EMA further attest to its consistent quality and compliance.

Importers should verify the following certifications when considering Biological E. Limited as a supplier:

• FDA Approval: Confirm the company's products are approved by the US Food and Drug Administration.

• WHO-GMP: Ensure the company holds Good Manufacturing Practice certification from the World Health Organization.

• EU GMP: Verify adherence to European Union Good Manufacturing Practice standards.

• ISO Certification: Check for relevant International Organization for Standardization certifications.

These certifications can typically be verified through the respective regulatory agencies' official websites or by contacting Biological E. Limited directly.

When conducting due diligence on Biological E. Limited, consider the following steps:

• Regulatory Compliance: Review the company's certifications and approvals from relevant regulatory bodies.

• Quality Assurance: Assess the company's adherence to international quality standards, including GMP certifications.

• Financial Stability: Evaluate the company's financial health through available financial statements and reports.

• Supply Chain Reliability: Investigate the company's supply chain practices and history of on-time deliveries.

Be cautious of red flags such as recent regulatory violations, quality control issues, or financial instability. Recommended pre-order checks include verifying product certifications, assessing the company's manufacturing capabilities, and reviewing customer feedback and testimonials.